Abstract
Abstract
Introduction
SARS-CoV-2 pandemic is especially compromising for patients with autoimmune diseases with or without immunomodulatory treatment. This study aimed to investigate the longitudinal changes in the health care of patients with immune-mediated neuropathies during the COVID-19 pandemic.
Methods
We performed a longitudinal study using questionnaires in a prospective cohort of patients with immune-mediated neuropathies at two timepoints of the pandemic: May–July 2021 and May–July 2022.
Results
The cohort consisted of 73 patients (55 male), mean age 62 years, 68 patients with CIDP, 5 with other immune neuropathies. In 2021, 19.2% of the patients reported a reduced number of physician–patient-contacts, while 13.7% reported this in 2022. Nevertheless, the overall health-care situation worsened from 2021 to 2022: 15.1% reported reduced overall healthcare in 2021, 26.0% in 2022. In 2021, 29.4% of patients reported absence of physio-/occupational therapy, while 34.4% reported this in 2022. Switching immunomodulatory treatment and stretching of treatment intervals occurred more often in 2022 (38.4%) than in 2021 (27.4%). 12 COVID-19-infections occurred overall, with typical only mild symptoms. The rate of fully vaccinated patients was 61.6% and 98.6% in May–July 2021 and 2022, respectively. Only minor side-effects after vaccination were reported.
Conclusion
Despite mitigation of COVID-19 restrictions from 2021 to 2022, the health-care situation of patients worsened in this time. Reasons could be the international shortage of immunoglobulins during the pandemic and reduced physio/ergotherapy due to lingering regulatory restrictions. Vaccination rate was high in our cohort of patients compared to the general German population and CIDP did not seem to be a risk factor for severe SARS-CoV-2 infections.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference29 articles.
1. Edouard Mathieu, Hannah Ritchie, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Joe Hasell, Bobbie Macdonald, Saloni Dattani, Diana Beltekian, Esteban Ortiz-Ospina, Max Roser (2020) Coronavirus Pandemic (COVID-19). OurWorldInData.org. https://ourworldindata.org/coronavirus. Accessed 31 Aug 2022
2. Robert Koch Institut Deutschland (2022) Coronavirus SARS-CoV-2—Informationen und Hilfestellungen für Personen mit einem höheren Risiko für einen schweren COVID-19-Krankheitsverlauf. Robert Koch Institut Deutschland. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/nCoV.html .Accessed 31 Aug 2022
3. Bertran Recasens B, Rubio MA (2020) Neuromuscular Diseases Care in the Era of COVID-19. Front Neurol. 11:588929
4. Fisse AL, Motte J, Grüter T, Sgodzai M, Pitarokoili K, Gold R (2020) Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy. Neurol Res Pract 2:42
5. Mathey EK, Park SB, Hughes RAC, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJB, Kiernan MC, Lin CS-Y (2015) Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86:973–985